A R L Medford1, L J Keen, J L Bidwell, A B Millar. 1. Lung Research Group, Department of Clinical Science at North Bristol, University of Bristol, Southmead Hospital, Westbury-on-Trym, Bristol BS10 5NB, UK.
Abstract
BACKGROUND: Non-cardiogenic pulmonary oedema is a characteristic feature of the acute respiratory distress syndrome (ARDS). The properties of vascular endothelial growth factor (VEGF) as a potent vascular permogen and mitogen have led to investigation of its potential role in this condition. Lower VEGF plasma levels have been linked to the presence of the T allele in the +936 CT polymorphism. We hypothesised that the presence of the T allele would be associated with the development and severity of ARDS. METHODS: A cohort of 137 normal subjects, 117 ventilated patients with ARDS, and 103 "at risk" of ARDS were genotyped for the VEGF+936 CT polymorphism. The severity of physiological disturbance and mortality was determined in the ventilated cohorts. RESULTS: The CT and TT genotype frequencies were increased in ARDS patients compared with both normal subjects (OR 2.01, 95% CI 1.13 to 3.58, p = 0.02) and those "at risk" (OR 2.05, 95% CI 1.02 to 2.20, p = 0.03). In patients with ARDS but not those "at risk", CT and TT genotypes were associated with a higher mean APACHE III score (80.9 (4.3) v 69.3 (2.9), p<0.05). CONCLUSION: These data support a role for VEGF in the pathogenesis of ARDS and its associated physiological derangement.
BACKGROUND:Non-cardiogenic pulmonary oedema is a characteristic feature of the acute respiratory distress syndrome (ARDS). The properties of vascular endothelial growth factor (VEGF) as a potent vascular permogen and mitogen have led to investigation of its potential role in this condition. Lower VEGF plasma levels have been linked to the presence of the T allele in the +936 CT polymorphism. We hypothesised that the presence of the T allele would be associated with the development and severity of ARDS. METHODS: A cohort of 137 normal subjects, 117 ventilated patients with ARDS, and 103 "at risk" of ARDS were genotyped for the VEGF+936 CT polymorphism. The severity of physiological disturbance and mortality was determined in the ventilated cohorts. RESULTS: The CT and TT genotype frequencies were increased in ARDS patients compared with both normal subjects (OR 2.01, 95% CI 1.13 to 3.58, p = 0.02) and those "at risk" (OR 2.05, 95% CI 1.02 to 2.20, p = 0.03). In patients with ARDS but not those "at risk", CT and TT genotypes were associated with a higher mean APACHE III score (80.9 (4.3) v 69.3 (2.9), p<0.05). CONCLUSION: These data support a role for VEGF in the pathogenesis of ARDS and its associated physiological derangement.
Authors: Y Kasahara; R M Tuder; L Taraseviciene-Stewart; T D Le Cras; S Abman; P K Hirth; J Waltenberger; N F Voelkel Journal: J Clin Invest Date: 2000-12 Impact factor: 14.808
Authors: G Matute-Bello; W C Liles; F Radella; K P Steinberg; J T Ruzinski; M Jonas; E Y Chi; L D Hudson; T R Martin Journal: Am J Respir Crit Care Med Date: 1997-12 Impact factor: 21.405
Authors: Veerle Compernolle; Koen Brusselmans; Till Acker; Peter Hoet; Marc Tjwa; Heike Beck; Stéphane Plaisance; Yuval Dor; Eli Keshet; Florea Lupu; Benoit Nemery; Mieke Dewerchin; Paul Van Veldhoven; Karl Plate; Lieve Moons; Désiré Collen; Peter Carmeliet Journal: Nat Med Date: 2002-06-10 Impact factor: 53.440
Authors: Anil Sapru; Joseph L Wiemels; John S Witte; Lorraine B Ware; Michael A Matthay Journal: Intensive Care Med Date: 2006-06-13 Impact factor: 17.440
Authors: Nuala J Meyer; Mingyao Li; Rui Feng; Jonathan Bradfield; Robert Gallop; Scarlett Bellamy; Barry D Fuchs; Paul N Lanken; Steven M Albelda; Melanie Rushefski; Richard Aplenc; Helen Abramova; Elena N Atochina-Vasserman; Michael F Beers; Carolyn S Calfee; Mitchell J Cohen; Jean-Francois Pittet; David C Christiani; Grant E O'Keefe; Lorraine B Ware; Addison K May; Mark M Wurfel; Hakon Hakonarson; Jason D Christie Journal: Am J Respir Crit Care Med Date: 2011-01-21 Impact factor: 21.405